GLP2-TR

Dual-pathway incretin research

A dual GIP/GLP-1 receptor agonist built on the tirzepatide structure for incretin-receptor signaling and structure-activity research - made in the USA and lot-traceable.

$130.00· 60 mg

View Certificate of Analysis

Bundle & saveStock up - research supply, ready to ship

Know exactly what’s in the vial.

How it works

Dual agonism at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).
GIPR-mediated cAMP signaling studied alongside glucose-dependent insulinotropic pathways in receptor models.
GLP-1R-mediated cAMP signaling studied in incretin-pathway and metabolic-response models.
Long-acting receptor exposure supported by a C20 fatty-diacid modification designed for albumin association.

Where it shines

Dual GIPR / GLP-1R receptor-signaling studies.
Incretin-pathway structure-activity and signaling-kinetics models.
Glucose-homeostasis and lipid-metabolism research models.

The specs, on the record

Amino-acid sequence39-residue GIP-based backbone with Aib substitutions at positions 2 and 13 and a C20 fatty-diacid modification

Molecular weight4813.5 g/mol

Molecular formulaC225H348N48O68

CAS number2023788-19-2

Research categoryMetabolic & Incretin Signaling

FormatMulti-dose vial · 60 mg

Stability & storage

Lyophilized powder - store at -20°C, protected from light.
Reconstituted - refrigerate 2-8°C; use within ~28-30 days.
Avoid repeated freeze-thaw cycles.

Backed by the science

The receipts. Peer-reviewed.

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

Coskun, T., et al. (2018). Molecular Metabolism.

doi:10.1016/j.molmet.2018.09.009 ↗

Every citation above is real, public, and linked. Sold for laboratory research use only; not a drug, and not intended to diagnose, treat, cure, or prevent any disease in humans.

Complete the stack

Researchers often pair GLP2-TR with

GLP3-RT

Dual-pathway and triple-pathway incretin research presented side by side for receptor-signaling comparisons.

$85.00View product

MOTS-c

Incretin-pathway research documented alongside mitochondrial-energy signaling models.

$50.00View product

NAD+

Metabolic receptor research sits adjacent to cellular-energy and longevity research.

$50.00View product